Chandan Healthcare reported a robust Q3 FY26, with Total Income hitting ₹65.77 Cr, a ~20% jump year-on-year.

EBITDA soared ~39% to ₹12.61 Cr, reflecting strong operating momentum and efficiency gains.

Net Profit after Minority Interest grew ~8% to ₹4.54 Cr.

For the nine months, Total Income rose ~21% to ₹203.27 Cr, EBITDA climbed ~39% to ₹42.59 Cr, and Net Profit increased ~25% to ₹20.14 Cr.

The company is strategically expanding, targeting 100 labs and 1,000 collection points across 17 states in three years, backed by a planned ₹100 Cr investment in expansion and advanced diagnostics.

Recent wins include an exclusive five-year partnership with Jeena Sikho Lifecare for comprehensive diagnostic services across 23 states, with operational rollout underway.

A significant B2G contract in Punjab (₹26 Cr, 10-year radiology project) and new advanced centers in Delhi and Bhopal further highlight growth.

Management expresses confidence in strengthening its pan-India presence and delivering sustainable long-term growth.

The company also raised ~₹104.13 Cr via warrants to fuel this expansion and potential acquisitions.